The Foot is Finally Past the Door With the NR today, Medisure has finally got a small footprint across the door and into the US market. With a population size 10x that of Canada it seems safe to assume that with FDA approval of its products and an annual run rate that should be above $2 million here in Canada ( let's see these financials over the next two weeks Steve) that a reasonable forecast for Medisure's combined annual revenues in both countries could well exceed $20 million.
This won't happen overnight but for those holding patiently this may be one of the most promising longterm possibilities finally nearing fruition. Will the second half of 2022 see Empower back on track?
GLTE!!!